Logo image of HYPR

HYPERFINE INC (HYPR) Stock Fundamental Analysis

NASDAQ:HYPR - Nasdaq - US44916K1060 - Common Stock - Currency: USD

1.12  -0.55 (-32.93%)

After market: 1.14 +0.02 (+1.79%)

Fundamental Rating

3

Overall HYPR gets a fundamental rating of 3 out of 10. We evaluated HYPR against 189 industry peers in the Health Care Equipment & Supplies industry. While HYPR has a great health rating, there are worries on its profitability. HYPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HYPR has reported negative net income.
HYPR had a negative operating cash flow in the past year.
HYPR Yearly Net Income VS EBIT VS OCF VS FCFHYPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -59.11%, HYPR is not doing good in the industry: 72.34% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -70.32%, HYPR is in line with its industry, outperforming 40.43% of the companies in the same industry.
Industry RankSector Rank
ROA -59.11%
ROE -70.32%
ROIC N/A
ROA(3y)-44.52%
ROA(5y)N/A
ROE(3y)-48.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HYPR Yearly ROA, ROE, ROICHYPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -10 -20 -30 -40 -50

1.3 Margins

The Gross Margin of HYPR (46.01%) is worse than 61.17% of its industry peers.
HYPR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 46.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HYPR Yearly Profit, Operating, Gross MarginsHYPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

HYPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
HYPR has more shares outstanding than it did 1 year ago.
There is no outstanding debt for HYPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HYPR Yearly Shares OutstandingHYPR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M
HYPR Yearly Total Debt VS Total AssetsHYPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -0.09, we must say that HYPR is in the distress zone and has some risk of bankruptcy.
HYPR's Altman-Z score of -0.09 is in line compared to the rest of the industry. HYPR outperforms 44.68% of its industry peers.
HYPR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.09
ROIC/WACCN/A
WACC9.13%
HYPR Yearly LT Debt VS Equity VS FCFHYPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

HYPR has a Current Ratio of 6.44. This indicates that HYPR is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HYPR (6.44) is better than 85.64% of its industry peers.
A Quick Ratio of 5.73 indicates that HYPR has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 5.73, HYPR belongs to the best of the industry, outperforming 85.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.44
Quick Ratio 5.73
HYPR Yearly Current Assets VS Current LiabilitesHYPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.64% over the past year.
Looking at the last year, HYPR shows a very strong growth in Revenue. The Revenue has grown by 61.90%.
Measured over the past years, HYPR shows a very strong growth in Revenue. The Revenue has been growing by 234.79% on average per year.
EPS 1Y (TTM)13.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)61.9%
Revenue growth 3Y234.79%
Revenue growth 5YN/A
Sales Q2Q%56.35%

3.2 Future

HYPR is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.57% yearly.
Based on estimates for the next years, HYPR will show a very strong growth in Revenue. The Revenue will grow by 22.17% on average per year.
EPS Next Y8.69%
EPS Next 2Y3.86%
EPS Next 3Y4.6%
EPS Next 5Y6.57%
Revenue Next Year18.23%
Revenue Next 2Y23.89%
Revenue Next 3Y24.04%
Revenue Next 5Y22.17%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HYPR Yearly Revenue VS EstimatesHYPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M
HYPR Yearly EPS VS EstimatesHYPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HYPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HYPR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HYPR Price Earnings VS Forward Price EarningsHYPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HYPR Per share dataHYPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.86%
EPS Next 3Y4.6%

More info and screens

0

5. Dividend

5.1 Amount

HYPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HYPERFINE INC

NASDAQ:HYPR (2/11/2025, 8:00:01 PM)

After market: 1.14 +0.02 (+1.79%)

1.12

-0.55 (-32.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners24.12%
Inst Owner Change-64.28%
Ins Owners4.64%
Ins Owner Change-0.24%
Market Cap81.70M
Analysts77.78
Price Target1.26 (12.5%)
Short Float %2.67%
Short Ratio10.95
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.96%
Min EPS beat(2)1.96%
Max EPS beat(2)1.96%
EPS beat(4)4
Avg EPS beat(4)7.16%
Min EPS beat(4)1.96%
Max EPS beat(4)18.3%
EPS beat(8)7
Avg EPS beat(8)4.34%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.7%
Min Revenue beat(2)8.33%
Max Revenue beat(2)9.07%
Revenue beat(4)3
Avg Revenue beat(4)-1.44%
Min Revenue beat(4)-28.96%
Max Revenue beat(4)9.07%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-9.46%
EPS NY rev (1m)0%
EPS NY rev (3m)2.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)9.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.16
P/FCF N/A
P/OCF N/A
P/B 1.4
P/tB 1.4
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.18
BVpS0.8
TBVpS0.8
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.11%
ROE -70.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 46.01%
FCFM N/A
ROA(3y)-44.52%
ROA(5y)N/A
ROE(3y)-48.79%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.98%
Cap/Sales 4.78%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.44
Quick Ratio 5.73
Altman-Z -0.09
F-Score5
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)169.11%
Cap/Depr(5y)N/A
Cap/Sales(3y)65.7%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
EPS Next Y8.69%
EPS Next 2Y3.86%
EPS Next 3Y4.6%
EPS Next 5Y6.57%
Revenue 1Y (TTM)61.9%
Revenue growth 3Y234.79%
Revenue growth 5YN/A
Sales Q2Q%56.35%
Revenue Next Year18.23%
Revenue Next 2Y23.89%
Revenue Next 3Y24.04%
Revenue Next 5Y22.17%
EBIT growth 1Y34.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.42%
EBIT Next 3Y7.1%
EBIT Next 5YN/A
FCF growth 1Y41.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.2%
OCF growth 3YN/A
OCF growth 5YN/A